Death domain containing receptor 5
    3.
    发明授权
    Death domain containing receptor 5 失效
    含有受体5的死亡域

    公开(公告)号:US07803615B1

    公开(公告)日:2010-09-28

    申请号:US09042583

    申请日:1998-03-17

    摘要: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.

    摘要翻译: 本发明涉及作为肿瘤坏死因子(TNF)受体家族的成员的新的含有死亡域的受体-5(DR5)蛋白,现在已经显示结合TRAIL。 特别地,提供编码人DR5蛋白的分离的核酸分子。 还提供了DR5多肽,载体,宿主细胞以及用于制备它们的重组方法。 本发明还涉及用于鉴定DR5活性的拮抗剂和拮抗剂的筛选方法。

    Antibodies against protective antigen
    4.
    发明授权
    Antibodies against protective antigen 有权
    针对保护性抗原的抗体

    公开(公告)号:US07601351B1

    公开(公告)日:2009-10-13

    申请号:US10602727

    申请日:2003-06-25

    IPC分类号: A61K39/395 A61K39/40

    CPC分类号: C07K16/00 C07K2317/56

    摘要: The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

    摘要翻译: 本发明涉及与炭疽芽孢杆菌(PA)的保护性抗原特异性结合的抗体和相关分子。 这样的抗体具有例如用于预防和治疗炭疽和炭疽毒素中毒的用途。 本发明还涉及编码抗PA抗体的核酸分子,含有这些核酸的载体和宿主细胞及其制备方法。

    Human Tumor Necrosis Factor Receptor-Like 2

    公开(公告)号:US20090092608A1

    公开(公告)日:2009-04-09

    申请号:US12241203

    申请日:2008-09-30

    摘要: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.

    Human Chemotactic Cytokine I Polypeptides
    7.
    发明申请
    Human Chemotactic Cytokine I Polypeptides 审中-公开
    人类趋化细胞因子I多肽

    公开(公告)号:US20090062510A1

    公开(公告)日:2009-03-05

    申请号:US11737622

    申请日:2007-04-19

    IPC分类号: C07K14/52

    CPC分类号: C07K14/52 C07H21/04

    摘要: Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.

    摘要翻译: 公开了人类趋化性细胞因子I多肽和编码这种趋化性细胞因子的DNA(RNA)以及通过重组技术产生此类多肽的方法。 还公开了利用这种趋化性细胞因子治疗白血病,肿瘤,慢性感染,自身免疫疾病,纤维化病症,伤口愈合和牛皮癣的方法。 还公开了抗这种趋化性细胞因子的拮抗剂及其作为治疗类风湿性关节炎,自身免疫,慢性和急性炎性和感染性疾病,过敏反应,前列腺素不依赖性发烧和骨髓衰竭的治疗剂的用途。 还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。 还公开了用于检测编码趋化性细胞因子的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定。

    Metalloproteinases
    10.
    发明授权
    Metalloproteinases 失效
    金属蛋白酶

    公开(公告)号:US07169566B2

    公开(公告)日:2007-01-30

    申请号:US10979092

    申请日:2004-11-02

    摘要: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.

    摘要翻译: 本发明涉及新型金属蛋白酶样蛋白质。 特别地,提供了分离的核酸分子,其编码人类TACE样和基质溶素样蛋白。 TACE样和基质溶素样多肽也可以作为载体,宿主细胞和用于制备它们的重组方法提供。 本发明进一步涉及用于鉴定TACE样和基质溶素样活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测癌症的诊断方法和癌症的治疗方法以及特征在于这些金属蛋白酶过度或过量生产的其它病症。